Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Novo Nordisk
BA
bactrian
Community Contributor
A Quality Compounder Marked Down on Overblown Fears
Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.
View narrative
US$120.72
FV
57.7% undervalued
intrinsic discount
15.71%
Revenue growth p.a.
Set Fair Value
26
users have liked this narrative
7
users have commented on this narrative
73
users have followed this narrative
New
narrative
ASML Holding
IN
Investingwilly
Community Contributor
Why Now is the Time to buy ASML
What Does ASML Do? ASML Holding N.V. is a Dutch company and the world’s only supplier of extreme ultraviolet (EUV) lithography machines —a critical technology used to produce the world’s most advanced computer chips.
View narrative
US$1.00k
FV
28.0% undervalued
intrinsic discount
15.17%
Revenue growth p.a.
Set Fair Value
35
users have liked this narrative
6
users have commented on this narrative
96
users have followed this narrative
Updated
narrative
Wyndham Hotels & Resorts
ZW
Zwfis
Community Contributor
Wyndham Continues Global Expansion with 19% Ancillary Revenue Growth
WH is a company that I actually took interest in a couple of months ago when I happened to stay at one of their franchise hotels. I had to leave early in the morning at like 4 and when I went out to the parking lot I was astounded that in the little town I was was absolutely full.
View narrative
US$105.80
FV
20.6% undervalued
intrinsic discount
13.23%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
1&1
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Proprietary 5G Network Expansion Will Strengthen European Digital Connectivity
Key Takeaways Transition to an independent 5G network will reduce long-term costs, improve margins, and boost future earnings despite short-term churn and elevated expenses. Rising data demand and regulatory support for local infrastructure will expand 1&1's market share and revenue potential, enhancing its competitive and financial stability.
View narrative
€20.29
FV
8.9% undervalued
intrinsic discount
1.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
Updated
narrative
Ekso Bionics Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Advanced Exoskeleton Devices Will Broaden Rehabilitation Market Access
Key Takeaways Accelerated adoption and revenue growth are expected from improved reimbursement, regulatory changes, and expanded distribution partnerships. Ongoing AI-driven innovation and recovery of delayed sales position Ekso Bionics for enhanced margins and future earnings stability.
View narrative
US$6.75
FV
n/a
intrinsic discount
43.97%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
Updated
narrative
Walker & Dunlop
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Pent-Up Financing Demand Will Drive Multifamily And Hospitality Transactions
Key Takeaways Strategic expansions and investment in talent and technology aim to diversify revenue and enhance efficiency, supporting growth in transaction volumes and margins. Walker & Dunlop's strong position in the multifamily sector, combined with market undersupply, is expected to drive significant revenue and earnings growth.
View narrative
US$92.50
FV
12.7% undervalued
intrinsic discount
10.23%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
Updated
narrative
Viemed Healthcare
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Expanding In-Home Clinical Services Will Unlock Opportunities In Respiratory And Mental Health Markets
Key Takeaways Viemed's expansion into underserved respiratory care and home-based healthcare aligns with market trends, potentially boosting revenue and improving margins. Strong financial health and no net debt position Viemed for strategic acquisitions, enhancing growth and long-term stability.
View narrative
US$13.00
FV
45.4% undervalued
intrinsic discount
12.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
Updated
narrative
Outset Medical
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Cost Cuts And Care Expansion Will Secure Success By 2025
Key Takeaways Outset Medical's expanding revenue from recurring sources and acute care markets underpins strong future growth prospects and console sales. Operational efficiency and recapitalization efforts enhance profitability and financial flexibility, setting the stage for sustainable growth.
View narrative
US$25.75
FV
50.3% undervalued
intrinsic discount
12.55%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
Updated
narrative
FTAI Aviation
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Aging Fleets And MRE Programs Will Sustain Service Demand
Key Takeaways Extended service life of current aircraft and engine delivery delays are driving stable, recurring demand and revenue growth for FTAI's engine maintenance solutions. Operational leverage, vertical integration, and strategic partnerships are boosting margins, expanding market share, and supporting stronger cash flow yields.
View narrative
US$183.55
FV
25.9% undervalued
intrinsic discount
16.61%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
3 days ago
author updated this narrative
Qorvo
AN
AnalystConsensusTarget
Consensus Narrative from 21 Analysts
Fifth-Generation And Sixth-Generation Networks Will Expand RF Solutions
Key Takeaways 5G/6G adoption and growing IoT device proliferation are driving multi-year revenue growth and diversification, reducing reliance on cyclical markets. Operational streamlining and expanding opportunities in defense and advanced wireless infrastructure are supporting sustained margin improvement and long-term growth.
View narrative
US$96.48
FV
8.7% undervalued
intrinsic discount
4.35%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
16
users have followed this narrative
3 days ago
author updated this narrative
Teradyne
AN
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
AI, Robotics And Automation Will Expand Silicon Photonics Testing
Key Takeaways Strategic focus on AI, robotics, and semiconductor automation aims to drive significant future revenue and net margin improvement. Quantifi Photonics acquisition and share buyback plan reflect confidence in earnings growth and market position strengthening.
View narrative
US$114.50
FV
6.1% undervalued
intrinsic discount
13.19%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
69
users have followed this narrative
Updated
narrative
uniQure
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
Key Takeaways Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment. Strategic financial actions and strong cash reserves provide resilience and flexibility, supporting pipeline advancement and likely improving margins.
View narrative
US$33.44
FV
60.3% undervalued
intrinsic discount
193.49%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
10 days ago
author updated this narrative
Value any company in seconds
Popular companies